Pharmaids Pharmaceuticals Share Price Today | Stock Price & Pharmaids Pharmaceuticals Share Screener
As of October 5, 2026, the live Pharmaids Pharmaceuticals share price (BSE: PHARMAID) is ₹30.15, unchanged from the previous close, with shares trading between ₹29.50 and ₹30.89 in today's trading session, and a 52-week range of ₹26.90–₹52.38. Check Pharmaids Pharmaceuticals 52-week for the annual price range and momentum. Use the Pharmaids Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Pharmaids Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹8 and net income of ₹2, with EBITDA of ₹4, an operating margin of -18.0% and a profit margin of 25.0%.
Pharmaids Pharmaceuticals Share Price Chart
Track the current stock price of Pharmaids Pharmaceuticals with an interactive chart. Analyse PHARMAID share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Pharmaids Pharmaceuticals stock quote in one place.
The quote of ₹30.15 sits between the 52-week low of ₹26.90 and the 52-week high of ₹52.38.
Pharmaids Pharmaceuticals Company Profile - Fundamental Screener
Screen Pharmaids Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PHARMAID shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE117D01018.
Company Details
Classification
Identifiers and Leadership
Pharmaids Pharmaceuticals Balance Sheet Screener
Screen PHARMAID balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹87, down from ₹120 in 2025.
Latest statistics put total assets at ₹87 and shareholder funds at ₹48, with a leverage ratio of 0.58.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
Assets |
|||||
| Total Assets | 87 | 120 | 91 | 25 | 11 |
| Current Assets | 11 | 21 | 14 | 18 | 3 |
| Fixed Assets | 54 | 77 | 63 | 0 | 0 |
Liabilities |
|||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 16 | 36 | 9 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||
| Total Equity | 48 | 55 | 71 | 23 | 9 |
| Share Capital | 35 | 35 | 35 | 21 | 10 |
| Reserves & Surplus | 12 | 24 | 37 | 1 | -2 |
Pharmaids Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Pharmaids Pharmaceuticals income statement and profit fundamentals. Analyze PHARMAID quarterly results. Pharmaids Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹8 and net profit was ₹2, equal to earnings per unit of ₹0.63, at an operating margin of -18%.
In that period expenses were ₹5, interest cost ₹1 and tax ₹1. The next period listed, 2026-Mar, shows revenue of ₹7 and net profit of ₹-1.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 8 | 7 | 6 | 12 | 7 | 5 | 5 | 5 | 5 | 6 | 1 | 0 | 0 | 0 | 0 |
| Expenses | 5 | 8 | 8 | 14 | 12 | 9 | 8 | 8 | 8 | 11 | 3 | 1 | 2 | 2 | 9 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 4 | 0 | -3 | -2 | -5 | -4 | -3 | -2 | -4 | -6 | -2 | -1 | -1 | -1 | -9 |
| Operating Profit % | -18.00% | -6.00% | -53.00% | -62.00% | -81.00% | -82.00% | -62.00% | -46.00% | -74.00% | -96.00% | -12200.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 2 | -2 | -4 | -4 | -7 | -5 | -4 | -3 | -4 | -7 | -2 | -1 | -1 | -1 | -9 |
| Tax | 1 | 0 | -1 | -1 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 | -2 |
| Net Profit | 2 | -1 | -3 | -3 | -5 | -5 | -3 | -2 | -3 | -6 | -1 | -1 | -1 | -1 | -6 |
| EPS | 0.63 | -0.51 | -0.70 | -0.70 | -1.39 | -1.11 | -0.55 | -0.73 | -0.76 | -2.82 | -0.54 | -0.24 | -0.61 | -0.61 | -4.76 |
Pharmaids Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen PHARMAID cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹4, and net cash flow was an outflow of ₹1.
Over the same period, investing activities provided ₹23 and financing activities used ₹20.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|---|
Cash from Operations and Investing | |||||
| Operating Activities | -4 | -15 | -11 | -4 | 0 |
| Investing Activities | 23 | -12 | -75 | -5 | 1 |
Financing and Net Cash | |||||
| Financing Activities | -20 | 23 | 78 | 21 | 0 |
| Net Cash Flow | -1 | -4 | -8 | 12 | 0 |
Pharmaids Pharmaceuticals Shareholding Pattern Screener
See Pharmaids Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Pharmaids Pharmaceuticals promoter holding and ownership changes for PHARMAID on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 32.99%, foreign institutions 0.00%, domestic institutions 0.00% and the public 47.44%, spread across 8,406 shareholders.
The shareholder count was 8,406 in 2026-Mar, compared with 8,632 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Apr |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 32.99% | 32.99% | 5.22% | 5.14% | 32.99% | 32.99% | 5.64% | 5.64% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 47.44% | 47.59% | 36.59% | 36.35% | 47.02% | 47.24% | 41.06% | 41.06% |
| Other Holding | 19.57% | 19.42% | 58.20% | 58.51% | 19.99% | 19.77% | 53.30% | 53.30% |
| Shareholder Count | 8,406 | 8,632 | 8,220 | 8,026 | 8,027 | 8,288 | 7,554 | 7,567 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Pharmaids Pharmaceuticals. Pharmaids Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
Pharmaids Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Pharmaids Pharmaceuticals stock. Check PHARMAID index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Pharmaids Pharmaceuticals Market Events Screener - Corporate Actions
Get Pharmaids Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Pharmaids Pharmaceuticals stock events that may affect PHARMAID share price, along with derivatives, futures and options activity and sector gainers.
14 corporate actions are listed, the most recent entry being Annual General Meeting dated September 11, 2026, with a record date of September 11, 2026.
It is followed by Quarterly Result Announcement dated August 12, 2026 and Quarterly Result Announcement dated May 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-11 | 2026-09-11 | Annual General Meeting | NA | -9.88% |
| 2026-08-12 | 2026-08-12 | Quarterly Result Announcement | NA | 5.59% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | -7.35% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | -0.69% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 0.44% |
| 2025-09-23 | 2025-09-23 | Annual General Meeting | NA | -4.35% |
| 2025-08-21 | 2025-08-21 | Quarterly Result Announcement | NA | 0.00% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | 0.43% |
| 2025-05-23 | 2025-05-23 | Quarterly Result Announcement | NA | -0.31% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -7.19% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 21.50% |
| 2024-09-25 | 2024-09-25 | Annual General Meeting | NA | -12.02% |
| 2024-01-31 | 2024-01-31 | Extraordinary General Meeting | NA | -1.74% |
| 2022-12-31 | 2022-12-31 | Extraordinary General Meeting | NA | 47.76% |
Pharmaids Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen PHARMAID competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Pharmaids Pharmaceuticals Company Announcements - News & Reports Screener
Screen PHARMAID latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 27, 2026.
The next most recent announcements are dated September 16, 2026 and September 15, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-27 | Closure of Trading Window | - |
| 2026-09-16 | Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-09-15 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-11 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-18 | Reg. 34 (1) Annual Report. | - |
| 2026-08-18 | Notice Of 37Th Annual General Meeting And Annual Report | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-12 | Submission Of Unaudited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-08-12 | Board Meeting Outcome for Board Meeting Outcome For August 12 2026 | - |
| 2026-08-06 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June 2026. | - |
| 2026-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-25 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-06-13 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015-Providing Corporate Guarantee To Subsidiary | - |
| 2026-05-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Submission Of Audited Financial Results Along With Auditors Report For The Quarter And Year Ended 31St March 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-22 | Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31St March 2026. | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹30.15, within a 52-week range of ₹26.90 to ₹52.38. The P/E ratio is -23.52 and the P/B ratio is 2.18, with earnings per unit of ₹-3.31. Market capitalisation stands at ₹106.35 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 5 balance sheet periods, 15 income statement periods, 5 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.